MedPath

Effect of Busulfan in left ventricular global lingitudinal strai

Phase 2
Conditions
Cardiomyopathy.
Cardiomyopathy
Registration Number
IRCT20191230045950N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Patients undergoing allogenic bone marrow transplantation

Exclusion Criteria

Diabetes melitus
Hypertension
Smoking
Family history of Ischemic heart disease
Major valvular heart disease
Hyperlipidemia
CKD
Obesity
Initial ejection fraction less than 55%

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eft ventricular function by Global longitudinal strain (GLS). Timepoint: At the begining of the study and 7 days after Busulfan therapy. Method of measurement: Echocardiography.
Secondary Outcome Measures
NameTimeMethod
eft ventricular end diastolic volume. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardoography.;Left ventricular end systolic volume. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardiography.;Left ventricular ejection fraction. Timepoint: At the begining and 7 days after Busulfan therapy. Method of measurement: Echocardiograghy.
© Copyright 2025. All Rights Reserved by MedPath